GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Possibilities of cognitive-affective disorders correction in patients with atopic dermatitis using selanc regulatory peptide
    LLC MedTestInfo ; 2020
    In:  Курский научно-практический вестник «Человек и его здоровье» , No. 3 ( 2020-09), p. 84-89
    Details
    In: Курский научно-практический вестник «Человек и его здоровье», LLC MedTestInfo, , No. 3 ( 2020-09), p. 84-89
    Abstract: Objective: To evaluate the efficacy of the selank regulatory peptide against cognitive-affective disorders in patients with atopic dermatitis (AD). Material and methods. The analysis of cognitive-affective disorders of 65 patients with atopic dermatitis (AD), randomized into 2 statistically comparable groups, was carried out. Patients of the first group received basic drug therapy (BT) for AD, the second group - a combination of selank and BT (S + BT) intranasally, 2 drops in each nasal passage, 3 times a day, for 14 days. The control group consisted of 30 healthy individuals. The levels of personal (LT) and reactive (RT) anxiety, alexithymia, the level of β-endorphin in the blood, and the quality of life (QOL) before treatment and after 30 days from its start were assessed. Results. In patients with AD, the level of RT was 4.2 times higher than in the control group, RT - 3.2 times, alexithymia - 18 times. In the BT group, 30 days after the start of treatment, RT decreased 1.4 times and RT - 1.3 times. In the C+BT group, the decrease in LT and RT was equally significant - by 2.4 times. The levels of alexithymia and blood β-endorphin in the BT group did not change significantly. In the S+BT group, alexithymicity of patients decreased by 1.2 times, and the level of β-endorphin in the blood increased by 1.9 times. The quality of life index in the BT group decreased 1.2 times after 30 days from the start of therapy, and 1.7 times in the S + BT group. Conclusion. Patients with AD are characterized by the increased levels of personal and reactive anxiety and alexithymia, which reduce their quality of life. The use of the selank regulatory peptide in the complex treatment of patients with AD has a corrective effect on affective-cognitive impairment, contributing to a decrease in the levels of personal and reactive anxiety, alexithymia, increases the level of β-endorphin in the blood and improves the quality of life of patients.
    Type of Medium: Online Resource
    ISSN: 1998-5746 , 1998-5754
    Uniform Title: Возможности коррекции когнитивно-аффективных расстройств у больных атопическим дерматитом с помощью регуляторного пептида селанка
    URL: Issue
    URL: Journal
    URL: Article
    DOI: 10.21626/vestnik/2020-3
    DOI: 10.21626/vestnik
    DOI: 10.21626/vestnik/2020-3/10
    Language: Unknown
    Publisher: LLC MedTestInfo
    Publication Date: 2020
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Fig. 3
    Farmarus Print Media ; 2021
    In:  Russian Journal of Allergy Vol. 18, No. 3 ( 2021-10-06), p. 44-92
    Details
    In: Russian Journal of Allergy, Farmarus Print Media, Vol. 18, No. 3 ( 2021-10-06), p. 44-92
    Abstract: Atopic dermatitis is one of the most common diseases (20‒40% among skin diseases) that occur in both genders worldwide and in different age groups. The problem urgency is caused by an increase in morbidity, a chronic relapsing course that often leads to a decrease in the quality of life and disability, low efficiency of traditional treatment methods, and limited access to contemporary effective targeted therapy. The clinical guidelines, which aimed to optimize care for patients with atopic dermatitis, contain up-to-date information on epidemiology, etiological factors, mechanisms of development and pathogenesis, aspects of the clinical presentation and disease course, current diagnostic methods (including allergological examination methods), as well as approaches to treatment (including traditional methods and modern targeted therapy). The indications for allergen-specific immunotherapy are determined, and the aspects of its implementation are described. The procedure for the provision of medical care, prevention, and follow-up monitoring is outlined. Clinical practice guidelines for atopic dermatitis are intended for practitioners of all specialties, students, teachers of medical schools, residents, graduate students, and researchers.
    Type of Medium: Online Resource
    ISSN: 2686-682X , 1810-8830
    URL: Issue
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    DOI: 10.36691/RJA.18.3
    DOI: 10.36691/RJA1474
    DOI: 10.36691/RJA1474-434
    DOI: 10.36691/RJA1474-435
    DOI: 10.36691/RJA1474-436
    Language: Unknown
    Publisher: Farmarus Print Media
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    The use of Cetirizine and Levocetirizine in patients with chronic urticaria and other allergic dermatoses: issues of dosage increasing and long-term use. Resolution of the Advisory Board
    Farmarus Print Media ; 2022
    In:  Russian Journal of Allergy Vol. 19, No. 3 ( 2022-10-07), p. 388-403
    Details
    In: Russian Journal of Allergy, Farmarus Print Media, Vol. 19, No. 3 ( 2022-10-07), p. 388-403
    Abstract: This article reflects the main issues discussed at the Advisory Board with the participation of leading dermatovenereologists, allergists, and immunologists. The Advisory Board has become a platform for discussing the accumulated clinical and organizational problems in the field of managing patients with chronic urticaria and other allergic dermatoses. The Advisory Board also discussed the possibility of long-term use of cetirizine and levocetirizine and the use of their high doses in clinical practice. The subject of discussion was the question of the algorithm for escalation and subsequent de-escalation of the dose of non-sedating H1 antihistamines. An algorithm for escalation and de-escalation of doses of antihistamines was created based on the discussion, which can be recommended for use in clinical practice. This article was simultaneously published in several journals with permission from authors and publishers. The parallel publication is available here: The use of cetirizine and levocetirizine in patients with chronic urticaria and other allergic dermatoses: Issues of dosage increasing and long-term use from the resolution of the Advisory Board. Effective Pharmacotherapy. 2022;18(25):614. DOI: https://doi.org/10.33978/2307-3586-2022-18-25-6-14. This article published with permission from authors and copyright holder.
    Type of Medium: Online Resource
    ISSN: 2686-682X , 1810-8830
    URL: Issue
    URL: Article
    DOI: 10.36691/RJA.19.3
    DOI: 10.36691/RJA1574
    Language: Unknown
    Publisher: Farmarus Print Media
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Practical issues in the use of emollients containing filaggrin modulators in the management of patients with atopic dermatitis and xerosis: Resolution of the Expert board
    Farmarus Print Media ; 2022
    In:  Russian Journal of Allergy Vol. 19, No. 2 ( 2022-06-06), p. 245-258
    Details
    In: Russian Journal of Allergy, Farmarus Print Media, Vol. 19, No. 2 ( 2022-06-06), p. 245-258
    Abstract: Leading experts in the field of dermatovenereology, cosmetology, and allergology took part in the meeting of the expert board. Following the discussion, the working groups of the Expert board assessed the role of filaggrin deficiency in the pathogenesis of atopic dermatitis and other diseases/conditions accompanied by xerosis. In addition, they formed recommendations for the use of emollient Admera, taking into account the role of filaggrin in the development of atopic dermatitis and xerosis. The experts comprehensively analyzed the best basic therapy for atopic dermatitis, xerosis of diverse etiologies secondary preventive options for atopic dermatitis and developed unified recommendations on the principles of managing such patients. In addition, they also established the place of emollients in clinical practice. Additional educational, informational, and organizationalactivities were proposed to help patients and doctors understand the problem of using emollients in atopic dermatitis and xerosis of diverse etiologies. This article was first published in the Kremlin Medicine Journal (Kruglova LS, Lvov AN, Araviyskaya ER, et al. Practical issues on the application of emollients containing filaggrin modulators in the management of patients with atopic dermatitis and xerosis. Resolution of the Council of experts. Kremlin Medicine Journal. 2022;1:8794. doi: 10.26269/m4bj-f167). This article published with permission from authors and copyright holder.
    Type of Medium: Online Resource
    ISSN: 2686-682X , 1810-8830
    URL: Issue
    URL: Article
    DOI: 10.36691/RJA.19.2
    DOI: 10.36691/RJA1538
    Language: Unknown
    Publisher: Farmarus Print Media
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Balneotherapy as a promising method for the correction of dermatologic adverse events of cancer therapy
    ECO-Vector LLC ; 2022
    In:  Russian Journal of Physiotherapy, Balneology and Rehabilitation Vol. 20, No. 6 ( 2022-09-15), p. 551-558
    Details
    In: Russian Journal of Physiotherapy, Balneology and Rehabilitation, ECO-Vector LLC, Vol. 20, No. 6 ( 2022-09-15), p. 551-558
    Abstract: Cancer treatment with chemotherapy, targeted and immunotherapy is associated with a wide spectrum of dermatologic adverse events. Xerosis (dryness) of the skin is the most prevalent skin side effect in oncologic patients, which occurs both during treatment with "classic" chemotherapy drugs and modern cancer drugs, such as targeted therapy and immunotherapy. Despite the high prevalence of this side effect, current approaches to the correction of skin xerosis in cancer patients are very limited. At the same time, in the absence of adequate supportive treatment of xerosis, the formation of persistent fissures, eczematization and secondary infection is observed, which may lead to antitumor therapy regimen modification. Thus, optimization of prophylactic and treatment strategies for xerosis in patients treated with anticancer drugs remain an important interdisciplinary problem. Balneotherapy is a promising method for the correction of skin xerosis due to a complex positive effect on the level of skin hydration, a decrease in the intensity of inflammatory processes, a beneficial effect on the state of the skin barrier function, as well as an increase in antimicrobial protection. Available data on the use of balneotherapy in the supportive treatment of skin xerosis as a dermatological adverse event of anticancer therapy confirms the high efficacy and safety, as well as good tolerability of this method in cancer patients.
    Type of Medium: Online Resource
    ISSN: 2413-2969 , 1681-3456
    URL: Article
    DOI: 10.17816/rjpbr108026
    Language: Unknown
    Publisher: ECO-Vector LLC
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Evaluation of effectiveness of combined supportive treatment for paronychia and pyogenic granulomas, associated with targeted anticancer therapy
    ECO-Vector LLC ; 2023
    In:  Russian Journal of Skin and Venereal Diseases Vol. 25, No. 6 ( 2023-02-17), p. 41-53
    Details
    In: Russian Journal of Skin and Venereal Diseases, ECO-Vector LLC, Vol. 25, No. 6 ( 2023-02-17), p. 41-53
    Abstract: BACKGROUND: Paronychia and pyogenic granulomas occur in 1050% of patients treated with epidermal growth receptor (EGFR) inhibitors. Supportive therapy for periungual lesions is challenging, since these adverse reactions are prone to torpidity and frequent relapses. AIM: to evaluate the effectiveness of supportive treatment for paronychia and pyogenic granulomas ― dermatologic adverse events of EGFR inhibitors, with a combined cream with betamethasone dipropionate, clotrimazole, gentamicin, and betaxolol solution. MATERIALS AND METHODS: 16 patients with paronychia and pyogenic granulomas associated with EGFR inhibitor therapy were included in a 12-week open-label prospective study. Paronychia and pyogenic granulomas severity assessment was performed with the NCI-CTCAE v. 5.0, a developed 10-point scale. The intensity of pain was assessed with a visual-analogue scale (VAS). The quality of life was assessed with the Dermatology Life Quality Index (DLQI). RESULTS: A significant improvement of all parameters (p 0.05) was evaluated from week 1, indicating the effective reduction of dermatologic adverse event objective and subjective symptoms, improvement of patients quality of life. By the end of the study, 37.5% of patients had complete resolution of lesions, 62.5% of patients had minimal residual erythema. Decrease of pain sensation in the affected periungual folds was observed throughout the study (p 0.05). DLQI score indicated the "small effect" of paronychia and pyogenic granulomas on patients life by the end of the study. CONCLUSIONS: Supportive treatment of paronychia and pyogenic granulomas with a combined cream with betamethasone dipropionate, clotrimazole and gentamicin and a betaxolol 0.25% solution is effective in the management of paronychia and pyogenic granulomas objective and subjective symptoms, has a high tolerability, allows to improve patients quality of life and continue targeted therapy without dose reduction. Long-term maintenance of pain sensation after paronychia and pyogenic granulomas resolution underlines the need for additional treatment options that will improve the effectiveness of pain management.
    Type of Medium: Online Resource
    ISSN: 2412-9097 , 1560-9588
    URL: Issue
    URL: Article
    DOI: 10.17816/dv.256
    DOI: 10.17816/dv112268
    Language: Unknown
    Publisher: ECO-Vector LLC
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Microsporia in Young Children: Clinical Cases
    Paediatrician Publishers LLC ; 2022
    In:  Current Pediatrics Vol. 21, No. 5 ( 2022-11-08), p. 400-406
    Details
    In: Current Pediatrics, Paediatrician Publishers LLC, Vol. 21, No. 5 ( 2022-11-08), p. 400-406
    Abstract: Background. Microsporia is a zooanthroponotic mycosis of skin and hair caused by fungi genus Microsporum. Microsporia is most common among children, including infants. The microsporia incidence has slow steady increase over recent years. Clinical cases description. Follow-up results of two children of different ages (younger/older than 1 year) with microsporia are presented. Successful management approach is shown. Major limitations of drug therapy in infants as well as common therapeutic errors were analyzed. Conclusion. Diagnosis and management of microsporia in infants and young children is a challenging task. Major errors in microsporia management in patients of these age groups are associated with peculiarities of clinical picture as well as limited variations of drugs that are appropriate for the requirements on efficacy and safety of therapy among young children.
    Type of Medium: Online Resource
    ISSN: 1682-5535 , 1682-5527
    URL: Article
    DOI: 10.15690/vsp.v21i5.2453
    Language: Unknown
    Publisher: Paediatrician Publishers LLC
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Psoriasis Comorbidities in Childhood
    Paediatrician Publishers LLC ; 2020
    In:  Current Pediatrics Vol. 19, No. 6 ( 2020-12-27), p. 460-467
    Details
    In: Current Pediatrics, Paediatrician Publishers LLC, Vol. 19, No. 6 ( 2020-12-27), p. 460-467
    Abstract: Psoriasis is multifactorial systemic disease characterized by excessive hyperkeratosis due to impaired keratinocytes proliferation and differentiation. This disease often manifests in childhood and it is usually associated with the development of comorbid conditions some of which are combined by the term «psoriatic march» (obesity, metabolic syndrome, etc.). The course of psoriasis and related comorbidities in children has several specific features that determine topicality of studying all the aspects of clinical diagnosis and prevention in childhood. The article summarizes recent ideas on the prevalence, pathogenesis features and early diagnosis of comorbid diseases in children with psoriasis.
    Type of Medium: Online Resource
    ISSN: 1682-5535 , 1682-5527
    URL: Article
    DOI: 10.15690/vsp.v19i6.2149
    Language: Unknown
    Publisher: Paediatrician Publishers LLC
    Publication Date: 2020
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    PSORIASIS VS MALIGNANCIES: POSSIBLE INTERRELATION AND POTENTIAL RISKS
    ECO-Vector LLC ; 2017
    In:  Russian Journal of Skin and Venereal Diseases Vol. 20, No. 5 ( 2017-12-15), p. 280-284
    Details
    In: Russian Journal of Skin and Venereal Diseases, ECO-Vector LLC, Vol. 20, No. 5 ( 2017-12-15), p. 280-284
    Abstract: To date one of the most discussed problems in the context of psoriasis is the possibility of correlation between the psoriatic process, considering its systemic nature, and the risk of cancer developing. Such interrelation can be caused both by systemic chronic inflammatory process and by methods of therapy. The purpose of this literature review is to assess the risk of developing malignant neoplasms of various organs and systems, as well as the factors that determine it, in patients with psoriasis in comparison with the general population. The mechanisms of action as well as early and remote side effects of the current treatment are described. The literature data on the risk of their carcinogenic effects are presented. The results of studies of a number of other factors acting as possible initiators of carcinogenesis in patients with psoriasis are highlighted, among them: the presence of a systemic inflammatory reaction, the severity and duration of the course of the disease, and also the comorbid states.
    Type of Medium: Online Resource
    ISSN: 2412-9097 , 1560-9588
    URL: Article
    DOI: 10.18821/1560-9588-2017-20-5-280-284
    Language: Unknown
    Publisher: ECO-Vector LLC
    Publication Date: 2017
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Janus kinase inhibitors efficacy for the treatment of adult atopic dermatitis in real clinical practice
    Farmarus Print Media ; 2023
    In:  Russian Journal of Allergy Vol. 20, No. 2 ( 2023-07-09), p. 238-249
    Details
    In: Russian Journal of Allergy, Farmarus Print Media, Vol. 20, No. 2 ( 2023-07-09), p. 238-249
    Abstract: Atopic dermatitis is a common chronic dermatosis characterized by a wide variability of endotypes and phenotypes. Approaches to the treatment of atopic dermatitis are currently undergoing significant changes, especially in patients with moderate and severe forms of atopic dermatitis. JAK inhibitors according to the results of numerous studies have shown their efficacy in the treatment of various immune-mediated dermatological diseases such as atopic dermatitis, vitiligo, focal alopecia and psoriasis, etc. The article presents the experience of treating adult patients suffering from a severe form of atopic dermatitis with the selective JAK-1 inhibitor upadacitinib. The observations presented are of particular interest due to the fact that the patients were treated with upadacitinib monotherapy. It should be noted that the drug is highly effective against itching. No adverse events (including the development of infectious diseases, hematological disorders) were registered during dynamic observation (according to the results of laboratory studies).
    Type of Medium: Online Resource
    ISSN: 2686-682X , 1810-8830
    URL: Issue
    URL: Article
    DOI: 10.36691/RJA.20.2
    DOI: 10.36691/RJA11544
    Language: Unknown
    Publisher: Farmarus Print Media
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...